Apple Inc. (AAPL.US) AirPods Pro 2 receives approval from the FDA in the United States, becoming a "over-the-counter hearing aid".
The Food and Drug Administration (FDA) has approved the hearing aid software for Apple's AirPods Pro 2, allowing them to be used as "over-the-counter hearing aids" in the United States.
The Food and Drug Administration (FDA) has approved the hearing aid software for Apple Inc.'s (AAPL.US) AirPods Pro 2, allowing the AirPods Pro 2 to be used as "over-the-counter hearing aids".
It is reported that the software's functions are aimed at individuals aged 18 and above, or those with mild to moderate hearing impairments. At the 2024 Apple Inc. fall product launch event, Apple Inc. announced that the AirPods Pro 2 will introduce some new hearing health-related features, with the updates set to be released later this year.
The updates include a default-enabled hearing protection mode (providing passive noise cancellation in noisy environments), as well as a "clinical-grade" hearing aid mode where users will conduct a brief hearing test using AirPods and iPhone. If hearing loss is detected, a "personalized sound configuration" file will be created, allowing the AirPods Pro 2 to dynamically adjust sound according to the user's needs to help them hear external sounds more easily.
Apple Inc. stated that the personalized hearing configurations will be automatically applied to music, movies, games, phone calls, and other scenarios without the need to adjust any settings. These features can help individuals better engage in conversations and stay connected with people and their surroundings.
Related Articles

Aerospace CH UAV (002389.SZ) plans to transfer the ownership of three parcels of land and buildings in Tazhou Nanyang Technology New Materials Industrial Park for no less than 408 million yuan.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): The innovative drug BIOS-0625 tablets have received the notice of clinical trial approval.

BQD (03866) received an increase in H shares of 243 million shares from its major shareholder Guoxin Financial Holdings Limited.
Aerospace CH UAV (002389.SZ) plans to transfer the ownership of three parcels of land and buildings in Tazhou Nanyang Technology New Materials Industrial Park for no less than 408 million yuan.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): The innovative drug BIOS-0625 tablets have received the notice of clinical trial approval.

BQD (03866) received an increase in H shares of 243 million shares from its major shareholder Guoxin Financial Holdings Limited.

RECOMMEND

Short Positions on Xiaomi (01810.HK) Surge 53% in a Week as Memory Price Spike Weighs on Sentiment
07/11/2025

Privatization Wave in Hong Kong Stocks: Exiting Liquidity Traps to Enable Strategic Transformation
07/11/2025

Over 30 Foreign Firms Attend Roundtable as Ministry of Commerce Signals Multiple Policy Shifts
07/11/2025


